These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 14650930)

  • 1. Clinical trial methods to discover and validate predictive markers for treatment response in cancer.
    Paik S
    Biotechnol Annu Rev; 2003; 9():259-67. PubMed ID: 14650930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Issues in clinical trial design for tumor marker studies.
    Sargent D; Allegra C
    Semin Oncol; 2002 Jun; 29(3):222-30. PubMed ID: 12063675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating many treatments and biomarkers in oncology: a new design.
    Kaplan R; Maughan T; Crook A; Fisher D; Wilson R; Brown L; Parmar M
    J Clin Oncol; 2013 Dec; 31(36):4562-8. PubMed ID: 24248692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designs of preoperative biomarkers trials in oncology: a systematic review of the literature.
    Marous M; Bièche I; Paoletti X; Alt M; Razak AR; Stathis A; Kamal M; Le Tourneau C
    Ann Oncol; 2015 Dec; 26(12):2419-28. PubMed ID: 26371283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy.
    Farwell MD; Clark AS; Mankoff DA
    JAMA Oncol; 2015 Jul; 1(4):421-2. PubMed ID: 26181243
    [No Abstract]   [Full Text] [Related]  

  • 7. Maurie Markman on the Groundbreaking TAPUR Trial.
    Markman M
    Oncology (Williston Park); 2017 Mar; 31(3):158, 168. PubMed ID: 28299751
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical trial designs for prospective validation of biomarkers.
    Mandrekar SJ; Grothey A; Goetz MP; Sargent DJ
    Am J Pharmacogenomics; 2005; 5(5):317-25. PubMed ID: 16196501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The arrival of predictive biomarkers for monitoring therapy response to natural compounds in cancer drug discovery.
    El Bairi K; Atanasov AG; Amrani M; Afqir S
    Biomed Pharmacother; 2019 Jan; 109():2492-2498. PubMed ID: 30551510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of chemoresponse assays as predictive markers.
    Korn EL; Freidlin B
    Br J Cancer; 2015 Feb; 112(4):621-3. PubMed ID: 25584494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do predictive signatures really predict response to cancer chemotherapy?
    Borst P; Wessels L
    Cell Cycle; 2010 Dec; 9(24):4836-40. PubMed ID: 21150277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?
    Gehan EA; Tefft MC
    J Natl Cancer Inst; 2000 Feb; 92(3):179-81. PubMed ID: 10655425
    [No Abstract]   [Full Text] [Related]  

  • 13. PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development.
    Hansen AR; Siu LL
    JAMA Oncol; 2016 Jan; 2(1):15-6. PubMed ID: 26562503
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase 0 clinical trials in oncology: an exploratory methodology for constructing a study with patients undergoing surgery for metastatic disease.
    Pocard M; Soria JC; Aldaz-Carroll L; Bellet D
    J Clin Oncol; 2010 Oct; 28(30):4551-3. PubMed ID: 20837954
    [No Abstract]   [Full Text] [Related]  

  • 15. [Biomarkers in solid tumors].
    Nagy Z
    Magy Onkol; 2013 Mar; 57(1):56-62. PubMed ID: 23573523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials.
    Ang JE; Kaye S; Banerji U
    Curr Drug Targets; 2012 Nov; 13(12):1525-34. PubMed ID: 22974395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trend toward noninferiority trials may mean more difficult interpretation of trial results.
    Tuma RS
    J Natl Cancer Inst; 2007 Dec; 99(23):1746-8. PubMed ID: 18042926
    [No Abstract]   [Full Text] [Related]  

  • 18. Predictive biomarkers: identification and verification.
    Yeatman TJ
    J Clin Oncol; 2009 Jun; 27(17):2743-4. PubMed ID: 19332709
    [No Abstract]   [Full Text] [Related]  

  • 19. Methodology of clinical trials in lung cancer.
    Menis J; Besse B; Lacombe D
    Chin Clin Oncol; 2015 Dec; 4(4):44. PubMed ID: 26730756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A risk management approach for imaging biomarker-driven clinical trials in oncology.
    Liu Y; deSouza NM; Shankar LK; Kauczor HU; Trattnig S; Collette S; Chiti A
    Lancet Oncol; 2015 Dec; 16(16):e622-8. PubMed ID: 26678215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.